A neu view of invasive lobular breast cancer.

ABSTRACT: Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.

SUBMITTER: Bose R 

PROVIDER: S-EPMC3700640 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature